Healthcare-focused investment firm Gilde has held a €145m final close on its original target for its latest transatlantic growth capital fund.
Gilde Healthcare III will target businesses in digital health, medical devices, diagnostics and therapeutics in the US and Europe.
The firm said hitting its target was a major achievement in the current fundraising environment, adding that investors were attracted by its strong track record.
It said the most recent successes were the $230m trade sale of Dutch hemostasis company ProFibrix to The Medicines Company and the IPO of Contus Pharam on the Nasdaq stock exchange.
The fund’s strategy focuses on companies which are delivering better healthcare solutions at lower cost, and will see it make equity investments of up to €15m in a single portfolio company.
GHC III has already invested in four companies and more are expected to be closed before year end, Gilde said.
The most recent investment was Sapiens, a Dutch neuro-modulation company focused on deep brain stimulation for patients suffering from Parkinson’s disease.
GHC III’s portfolio also includes Inovalabs, which markets portable oxygen concentrators for patients with respiratory conditions, iWalk, which commercializes bionic prosthetics for lower leg amputees, and Definiens, the leading provider of image analysis software for digital pathology.
The firm plans to make up to twelve investments using the fund.
Copyright © 2013 AltAssets